Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases

被引:3
作者
Gluba-Brzozka, Anna [1 ]
Franczyk, Beata [2 ]
Olszewski, Robert [3 ]
Banach, Maciej [4 ]
Rysz, Jacek [2 ]
机构
[1] WAM Teaching Hosp, Dept Nephrol Hypertens & Family Med, PL-90549 Lodz, Poland
[2] Med Univ Lodz, Dept Nephrol Hypertens & Family Med, PL-90549 Lodz, Poland
[3] Polish Acad Sci IPPT PAN, Inst Fundamental Technol Res, Dept Ultrasound, PL-02106 Warsaw, Poland
[4] Med Univ Lodz, Dept Hypertens, PL-90549 Lodz, Poland
关键词
renal diseases; personalized medicine; treatment; diagnosis; biomarkers; CHRONIC KIDNEY-DISEASE; DOMINANT POLYCYSTIC KIDNEY; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; SINGLE-NUCLEOTIDE POLYMORPHISMS; GELATINASE-ASSOCIATED LIPOCALIN; S-METHYLTRANSFERASE DEFICIENCY; ACID-BINDING PROTEIN; UROKINASE RECEPTOR; GENE POLYMORPHISM; APOL1; VARIANTS;
D O I
10.3390/ijms18061248
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The prevalence of renal diseases is rising and reaching 5-15% of the adult population. Renal damage is associated with disturbances of body homeostasis and the loss of equilibrium between exogenous and endogenous elements including drugs and metabolites. Studies indicate that renal diseases are influenced not only by environmental but also by genetic factors. In some cases the disease is caused by mutation in a single gene and at that time severity depends on the presence of one or two mutated alleles. In other cases, renal disease is associated with the presence of alteration within a gene or genes, but environmental factors are also necessary for the development of disease. Therefore, it seems that the analysis of genetic aspects should be a natural component of clinical and experimental studies. The goal of personalized medicine is to determine the right drug, for the right patient, at the right time. Whole-genome examinations may help to change the approach to the disease and the patient resulting in the creation of personalized medicine" with new diagnostic and treatment strategies designed on the basis of genetic background of each individual. The identification of high-risk patients in pharmacogenomics analyses will help to avoid many unwarranted side effects while optimizing treatment efficacy for individual patients. Personalized therapies for kidney diseases are still at the preliminary stage mainly due to high costs of such analyses and the complex nature of human genome. This review will focus on several areas of interest: renal disease pathogenesis, diagnosis, treatment, rate of progression and the prediction of prognosis.
引用
收藏
页数:20
相关论文
共 133 条
[1]   Perspective: Does personalized medicine hold the future for medicine [J].
Agyeman, Akosua Adom ;
Ofori-Asenso, Richard .
JOURNAL OF PHARMACY AND BIOALLIED SCIENCES, 2015, 7 (03) :239-244
[2]   MicroRNAs in kidney function and disease [J].
Akkina, Sanjeev ;
Becker, Bryan N. .
TRANSLATIONAL RESEARCH, 2011, 157 (04) :236-240
[3]   The GYF domain protein CD2BP2 is critical for embryogenesis and podocyte function [J].
Albert, Gesa I. ;
Schell, Christoph ;
Kirschner, Karin M. ;
Schaefer, Sebastian ;
Naumann, Ronald ;
Mueller, Alexandra ;
Kretz, Oliver ;
Kuropka, Benno ;
Girbig, Mathias ;
Huebner, Norbert ;
Krause, Eberhard ;
Scholz, Holger ;
Huber, Tobias B. ;
Knobeloch, Klaus-Peter ;
Freund, Christian .
JOURNAL OF MOLECULAR CELL BIOLOGY, 2015, 7 (05) :402-414
[4]   A haplotype map of the human genome [J].
Altshuler, D ;
Brooks, LD ;
Chakravarti, A ;
Collins, FS ;
Daly, MJ ;
Donnelly, P ;
Gibbs, RA ;
Belmont, JW ;
Boudreau, A ;
Leal, SM ;
Hardenbol, P ;
Pasternak, S ;
Wheeler, DA ;
Willis, TD ;
Yu, FL ;
Yang, HM ;
Zeng, CQ ;
Gao, Y ;
Hu, HR ;
Hu, WT ;
Li, CH ;
Lin, W ;
Liu, SQ ;
Pan, H ;
Tang, XL ;
Wang, J ;
Wang, W ;
Yu, J ;
Zhang, B ;
Zhang, QR ;
Zhao, HB ;
Zhao, H ;
Zhou, J ;
Gabriel, SB ;
Barry, R ;
Blumenstiel, B ;
Camargo, A ;
Defelice, M ;
Faggart, M ;
Goyette, M ;
Gupta, S ;
Moore, J ;
Nguyen, H ;
Onofrio, RC ;
Parkin, M ;
Roy, J ;
Stahl, E ;
Winchester, E ;
Ziaugra, L ;
Shen, Y .
NATURE, 2005, 437 (7063) :1299-1320
[5]   An integrated map of genetic variation from 1,092 human genomes [J].
Altshuler, David M. ;
Durbin, Richard M. ;
Abecasis, Goncalo R. ;
Bentley, David R. ;
Chakravarti, Aravinda ;
Clark, Andrew G. ;
Donnelly, Peter ;
Eichler, Evan E. ;
Flicek, Paul ;
Gabriel, Stacey B. ;
Gibbs, Richard A. ;
Green, Eric D. ;
Hurles, Matthew E. ;
Knoppers, Bartha M. ;
Korbel, Jan O. ;
Lander, Eric S. ;
Lee, Charles ;
Lehrach, Hans ;
Mardis, Elaine R. ;
Marth, Gabor T. ;
McVean, Gil A. ;
Nickerson, Deborah A. ;
Schmidt, Jeanette P. ;
Sherry, Stephen T. ;
Wang, Jun ;
Wilson, Richard K. ;
Gibbs, Richard A. ;
Dinh, Huyen ;
Kovar, Christie ;
Lee, Sandra ;
Lewis, Lora ;
Muzny, Donna ;
Reid, Jeff ;
Wang, Min ;
Wang, Jun ;
Fang, Xiaodong ;
Guo, Xiaosen ;
Jian, Min ;
Jiang, Hui ;
Jin, Xin ;
Li, Guoqing ;
Li, Jingxiang ;
Li, Yingrui ;
Li, Zhuo ;
Liu, Xiao ;
Lu, Yao ;
Ma, Xuedi ;
Su, Zhe ;
Tai, Shuaishuai ;
Tang, Meifang .
NATURE, 2012, 491 (7422) :56-65
[6]   The role of non-coding RNAs in diabetic nephropathy: Potential applications as biomarkers for disease development and progression [J].
Alvarez, M. Lucrecia ;
DiStefano, Johanna K. .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2013, 99 (01) :1-11
[7]   Increased transcriptional activity of the CYP3A4* 1B promoter variant [J].
Amirimani, B ;
Ning, B ;
Deitz, AC ;
Weber, BL ;
Kadlubar, FF ;
Rebbeck, TR .
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2003, 42 (04) :299-305
[8]  
[Anonymous], 2020, VOLUME MODE TRAVELIN
[9]  
[Anonymous], 2005, FARL PERL SCI AN GEN
[10]  
[Anonymous], PROGR BUDG TOOLS DAT